These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1137 related items for PubMed ID: 10873077

  • 1. Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.
    Freedman RS, Kudelka AP, Kavanagh JJ, Verschraegen C, Edwards CL, Nash M, Levy L, Atkinson EN, Zhang HZ, Melichar B, Patenia R, Templin S, Scott W, Platsoucas CD.
    Clin Cancer Res; 2000 Jun; 6(6):2268-78. PubMed ID: 10873077
    [Abstract] [Full Text] [Related]

  • 2. HLA class I expression on human ovarian carcinoma cells correlates with T-cell infiltration in vivo and T-cell expansion in vitro in low concentrations of recombinant interleukin-2.
    Kooi S, Zhang HZ, Patenia R, Edwards CL, Platsoucas CD, Freedman RS.
    Cell Immunol; 1996 Dec 15; 174(2):116-28. PubMed ID: 8954611
    [Abstract] [Full Text] [Related]

  • 3. Cytokine production by T-cell lines derived from tumor-infiltrating lymphocytes from patients with ovarian carcinoma: tumor-specific immune responses and inhibition of antigen-independent cytokine production by ovarian tumor cells.
    Kooi S, Freedman RS, Rodriguez-Villanueva J, Platsoucas CD.
    Lymphokine Cytokine Res; 1993 Dec 15; 12(6):429-37. PubMed ID: 8123759
    [Abstract] [Full Text] [Related]

  • 4. Intraperitoneal recombinant gamma-interferon in patients with recurrent ascitic ovarian carcinoma: modulation of cytotoxicity and cytokine production in tumor-associated effectors and of major histocompatibility antigen expression on tumor cells.
    Allavena P, Peccatori F, Maggioni D, Erroi A, Sironi M, Colombo N, Lissoni A, Galazka A, Meiers W, Mangioni C.
    Cancer Res; 1990 Nov 15; 50(22):7318-23. PubMed ID: 2121337
    [Abstract] [Full Text] [Related]

  • 5. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.
    Woo EY, Chu CS, Goletz TJ, Schlienger K, Yeh H, Coukos G, Rubin SC, Kaiser LR, June CH.
    Cancer Res; 2001 Jun 15; 61(12):4766-72. PubMed ID: 11406550
    [Abstract] [Full Text] [Related]

  • 6. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix.
    Santin AD, Ravaggi A, Bellone S, Pecorelli S, Cannon M, Parham GP, Hermonat PL.
    Gynecol Oncol; 2001 Jun 15; 81(3):424-32. PubMed ID: 11371133
    [Abstract] [Full Text] [Related]

  • 7. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
    Bukowski RM, Sharfman W, Murthy S, Rayman P, Tubbs R, Alexander J, Budd GT, Sergi JS, Bauer L, Gibson V.
    Cancer Res; 1991 Aug 15; 51(16):4199-205. PubMed ID: 1868441
    [Abstract] [Full Text] [Related]

  • 8. Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes.
    Ogasawara M, Rosenberg SA.
    Cancer Res; 1993 Aug 01; 53(15):3561-8. PubMed ID: 8101762
    [Abstract] [Full Text] [Related]

  • 9. Phase I study of intraperitoneal recombinant human interleukin 12 in patients with Müllerian carcinoma, gastrointestinal primary malignancies, and mesothelioma.
    Lenzi R, Rosenblum M, Verschraegen C, Kudelka AP, Kavanagh JJ, Hicks ME, Lang EA, Nash MA, Levy LB, Garcia ME, Platsoucas CD, Abbruzzese JL, Freedman RS.
    Clin Cancer Res; 2002 Dec 01; 8(12):3686-95. PubMed ID: 12473577
    [Abstract] [Full Text] [Related]

  • 10. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
    Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF.
    Cancer Res; 1990 Oct 01; 50(19):6302-10. PubMed ID: 2205379
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. [Effects of auto-tumor infiltrating lymphocytes induced by interleukin (IL)-12 with IL-2 on patients of primary hepatic carcinoma].
    Zhang YX, Wang XY, Liu JB, Zhang SQ, Chen YR.
    Zhonghua Yi Xue Za Zhi; 2008 Apr 08; 88(14):973-6. PubMed ID: 18756970
    [Abstract] [Full Text] [Related]

  • 14. Correlation of NK T-like CD3+CD56+ cells and CD4+CD25+(hi) regulatory T cells with VEGF and TNFalpha in ascites from advanced ovarian cancer: Association with platinum resistance and prognosis in patients receiving first-line, platinum-based chemotherapy.
    Bamias A, Koutsoukou V, Terpos E, Tsiatas ML, Liakos C, Tsitsilonis O, Rodolakis A, Voulgaris Z, Vlahos G, Papageorgiou T, Papatheodoridis G, Archimandritis A, Antsaklis A, Dimopoulos MA.
    Gynecol Oncol; 2008 Feb 08; 108(2):421-7. PubMed ID: 18036640
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma.
    Sheu BC, Chiou SH, Lin HH, Chow SN, Huang SC, Ho HN, Hsu SM.
    Cancer Res; 2005 Apr 01; 65(7):2921-9. PubMed ID: 15805295
    [Abstract] [Full Text] [Related]

  • 17. Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance.
    Bamias A, Tsiatas ML, Kafantari E, Liakou C, Rodolakis A, Voulgaris Z, Vlahos G, Papageorgiou T, Tsitsilonis O, Bamia C, Papatheodoridis G, Politi E, Archimandritis A, Antsaklis A, Dimopoulos MA.
    Gynecol Oncol; 2007 Jul 01; 106(1):75-81. PubMed ID: 17433425
    [Abstract] [Full Text] [Related]

  • 18. Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors.
    Heo DS, Whiteside TL, Kanbour A, Herberman RB.
    J Immunol; 1988 Jun 01; 140(11):4042-9. PubMed ID: 3286766
    [Abstract] [Full Text] [Related]

  • 19. Lymphocytes infiltrating human ovarian tumors: synergy between tumor necrosis factor alpha and interleukin 2 in the generation of CD8+ effectors from tumor-infiltrating lymphocytes.
    Wang YL, Si LS, Kanbour A, Herberman RB, Whiteside TL.
    Cancer Res; 1989 Nov 01; 49(21):5979-85. PubMed ID: 2507139
    [Abstract] [Full Text] [Related]

  • 20. Local/regional recombinant interleukin 2 (rIL-2) immunotherapy of tumors. Intra-arterial continuous infusion of rIL-2 in bladder cancer patients: a phase I study.
    Velotti F, Tubaro A, Stoppacciaro A, Pettinato A, Morrone S, Bossola P, Napolitano T, Miano L, Ruco L, Piccoli M.
    Ann Ist Super Sanita; 1990 Nov 01; 26(3-4):411-21. PubMed ID: 2091503
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 57.